Double Your Impact: May Fundraisers Matched Dollar-For-Dollar!

By Cody R. Barnett, MRA Director of Communications | 18 April 2019 In Allies & Partnerships, News

Thanks to a generous matching gift from our co-founders, Debra and Leon Black, every donation made to MRA through an individual fundraising campaign in May, will be matched dollar-for-dollar, up to $65,000.*

Read More


Building Community While Raising More than $10 Million for Melanoma

By Cody R. Barnett, MRA Director of Communications | 15 April 2019 In Allies & Partnerships, Events

Leveraged Finance Fights Melanoma has become an annual event that brings over 1,000 people together from the leveraged finance and private equity community. Cofounder Brendan Dillon shares his own journey with melanoma.

Read More


Melanoma Vaccines Show Promise

14 April 2019 In Science, Treatment

While immunotherapy has transformed way melanoma is treated, about half of patients still do not respond. Researchers are pursuing multiple strategies to understand why this happens and to develop strategies to jumpstart a response. One approach showing promise in early clinical trials, comes in the form of new personalized vaccines being developed by Ugur Sahin of Johannes Gutenberg-Universität Mainz and BioNTech.

Read More


What’s Next for the Microbiome in Melanoma?

By Kristen Mueller, Ph.D., MRA Scientific Program Director | 11 April 2019 In Science, Treatment

We know that the billions of bacteria that live in our bodies can impact the way we respond to immunotherapy, but can we harness this help more patients respond these life-saving drugs?

Read More


This Engineer is Building a ‘Better’ Biopsy

By Cody R. Barnett, MRA Director of Communications | 20 March 2019 In Science

Biopsies are an important tool to determine if a mole or other lesion is cancerous. For most patients, the occasional biopsy is no big deal. However for patients facing multiple abnormal or otherwise ‘suspicious’ spots in highly visible places the prospect can be daunting. Dr. Jesse Wilson, an MRA-funded investigator, is an engineer on a mission to build a better biopsy.

Read More


Bronze Bodies and Black Lungs: Five Ways the Tanning and Tobacco Industries Use the Same Playbook

By Charles Brodine, MRA Intern | 17 March 2019 In Prevention, Science

Dr. Alan Blum has crusaded against the tobacco industry for 30 years and now he's taking aim at the tanning industry. According to Blum, both the tobacco and tanning industries exploit people in similar ways, by targeting youth, downplaying their own corporate responsibility, infiltrating pop-culture, and indeed, by becoming prolific icons.

Read More


Is it Working? Imaging the Immune Response in Melanoma

14 March 2019

Traditional imaging – such as MRIs or CAT scans – provide insight into the effectiveness of immunotherapy by measuring tumor size. While this works, some patients may take months to respond to immunotherapy and in other cases, tumors may appear to actually grow on these scans, falsely indicating progression.

Read More


How Jaqueline’s Promise and Persistence Paid Off

5 March 2019 In Melanoma Stories

Melanoma wasn't supposed to happen to Jacqueline. Melanoma was supposed to be a disease that older, white women got, not 21-year-old African Americans. "People often think having more melanin makes them from developing melanoma. But they’re wrong,” Jacqueline says.

Read More


Fight Back Give Back with Clinical Trials

By Cody R. Barnett, MRA Director of Communications | 24 February 2019 In News, Science

When patients understand all of their options, including clinical trials, they can make informed decisions about their care. For many patients, clinical trials represent the best possible way to get access to cutting-edge treatment options.

Read More


Overcoming Targeted Therapy Resistance

By Marc Hurlbert, Ph.D., MRA Chief Science Officer | 22 February 2019 In Science, Treatment

Targeted therapies work well for many patients, but most will go on to develop acquired resistance. Researchers are working to address this challenge. Learn about two promising examples.

Read More


Login

×